Journal article
Prospective longitudinal assessment of Albumin-to-Creatinine ratio (ACR) in a clinical cohort of people living with HIV in Gaborone
Research Areas Currently no objects available |
Publication Details Author list: Mosepele Mosepele1,2,3*, Kago Kebotsamang4 Publisher: Springer Nature Switzerland Publication year: 2025 Journal: BMC Infectious Diseases Volume number: 25 Issue number: 1 ISSN: 1471-2334 eISSN: 1471-2334 |
Background People living with HIV (PLWH) in sub-Saharan Africa are vulnerable to end organ dysfunction such as albuminuria, which is associated with an increased risk of cardiovascular and renal events. However, the prevalence of persistent albuminuria among PLWH in Africa is unclear. This observational prospective study assessed for persistence of albuminuria in a cohort of PLWH on longterm antiretroviral therapy (ART) across various HIV service platforms in Gaborone, Botswana. Methods A subgroup of ART treated PLWH (n=867) from a larger cross-sectional study (n=1537) assessing prevalence of albuminuria among PLWH at a referral hospital HIV clinic and satellite HIV clinics in Gaborone, were invited to participate in a 12-month long albuminuria prospective cohort study between January 2020 and March 2022. During three planned study visits, albumin-creatinine (ACR) was computed using urine albumin measured using immunoturbidimetric assay and urine creatinine using colorimetric assay (Jaffe method), at the Botswana Harvard HIV Reference Laboratory. ACR trajectory groups were identified using growth mixture models, and factors associated with ACR trajectory were analyzed using modified Poisson regression. Results Among the 623 adults with complete data for all 3 study visits, their baseline median age was 50 (42–57) years with a median HIV disease duration of 13.1 (8.7–16.7) years, and 266 (42.7%) of them were female. Study participants were categorized into two ACR trajectory groups: low increasing ACR, N=290 (46.5%) and moderate increasing ACR, N=333 (53.5%) groups. ACR increased by 4.7 mg/g in the slow increasing ACR groups versus 11.5 mg/g in the moderate increasing ACR trajectory group by end of follow-up. Active use of Tenofovir, aRR 1.27 [95% CI 1.02–1.60], p=0.036, or ACEi/ARB, aRR 1.31 [95% CI 1.07–1.61], p=0.008, and an elevated baseline ACR, aRR 1.34 [95% CI 1.28–1.41], p<0.001, were all associated with being in the moderate increasing ACR trajectory group.
Projects
Currently no objects available
Currently no objects available |
Documents
Currently no objects available